%0 Journal Article %T Iron deficiency in pulmonary arterial hypertension: perspectives %+ Pôle des Cardiopathies Congénitales du Nouveau-Né à L'adulte - Centre Constitutif Cardiopathies Congénitales Complexes M3C, Groupe Hospitalier Paris Saint-Joseph, Hôpital Marie-Lannelongue, Inserm U999, Université Paris-Saclay %+ Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)) %+ Hôpital Lariboisière-Fernand-Widal [APHP] %A Quatredeniers, Marceau %A Montani, David %A Cohen‐solal, Alain %A Perros, Frédéric %< avec comité de lecture %@ 2045-8932 %J Pulmonary circulation / Pulm Circ %I Publisher : Mumbai : Medknow Publications - Latest Publisher : Jan. 2017- : Thousand Oaks, CA : Sage Publishing %V 11 %N 3 %P 20458940211021301 %8 2021-06 %D 2021 %R 10.1177/20458940211021301 %M 34178305 %K right heart failure %K hepcidin %K iron supplementation %Z Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemJournal articles %X In left heart failure, iron supplementation (IS) is a first-line treatment option, regardless of anemia. Pulmonary arterial hypertension (PAH), a rare disease leading to right heart failure, is also associated with iron deficiency. While it is a much debated topic, recent evidence demonstrate that restoration of iron stores results in improved right ventricular function and exercise tolerance. Hence, IS may also be considered as an option in the treatment of PAH. %G English %2 https://inserm.hal.science/inserm-03934812/document %2 https://inserm.hal.science/inserm-03934812/file/10.1177_20458940211021301.pdf %L inserm-03934812 %U https://inserm.hal.science/inserm-03934812 %~ INSERM %~ UNIV-PARIS13 %~ CNRS %~ APHP %~ CARDIO %~ UNIV-PARIS-SACLAY %~ SORBONNE-PARIS-NORD %~ UNIV-PARIS %~ UNIVERSITE-PARIS %~ UP-SANTE %~ UNIVERSITE-PARIS-SACLAY